Wilson Sonsini Goodrich & Rosati advised investor Novo Holdings on the transaction.Obsidian Therapeutics, Inc. (Obsidian), a clinical-stage biotechnology company, announced it closed an oversubscribed $160.5 million…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
